Barry Levenfeld has a wide-ranging technology and life-science practice focusing on mergers and acquisitions (representing both global technology companies and Israeli target companies); fund formation and portfolio investment for Israeli and overseas private equity and venture capital funds; representation of technology and life science start-up companies from first seed financing through acquisition or initial public offering and beyond; intellectual property transactional work including distribution, OEM, licensing strategic collaboration, joint venture and marketing agreements; life science companies and academic institutions; internet and multimedia issues; and representation in Israel of major international technology companies.
Barry is a Senior Lecturer at the Faculty of Law of the Hebrew University in Jerusalem, serves on the board of the Israel Union for Environmental Defense and of Alyn Hospital, and is a an avid biker and one of the founders and organizers of the Wheels of Love Annual Charity Bike Ride, Israel's premier charity biking event.
Barry graduated from Harvard College summa cum laude in 1976 and from Harvard Law School in 1980. Barry was admitted to the New York Bar in 1981 and to the Israel Bar in 1985.
Barry’s numerous recognitions include his rankings by Chambers Global in three categories: Israel, Corporate M&A (Band 1); Israel Capital Markets; and Israel TMT: Corporate (“one of the top lawyers in the country”; an immensely experienced M&A practitioner”; “highly regarded in the pharmaceutical field”; “one of the most prominent names in the hi-tech market”). Barry has also been designated by Geektime magazine as one of the 100 most influential people in Israeli high-tech and has earned repeated top rankings from such publications as IFLR1000, The Legal 500 (a ‘Leading Individual’ in Healthcare and Life Sciences, among other honors), LMG Life Sciences, Euromoney, and Legal Experts’ Europe, Middle East & Africa guide.
Who’s Who Legal ranks Barry as being among the world’s leading attorneys in the Capital Markets, M&A, Corporate Governance and Transactional Life Sciences fields.
Barry joined the firm in 1988 and became a partner in 1992.